Clinical investigator, Dr. Dore participates as a Principal Investigator in clinical research studies of medications for treatment of gout, osteoarthritis, osteoporosis, rheumatoid arthritis, Lupus, metabolic bone and other auto-immune diseases. She has investigated multiple phase trials for over the last 30+ years. Studied agents include, but not limited to: anti-TNF, anti-IL1, COX-2, RANK ligand inhibitor, selective estrogen receptor modulator, parathyroid hormone, Anti-Blyss antibodies, anti- IL-17, anti-IL-23 and other agents.
Please click here to find out about Current Enrolling Studies.
To CONTACT US:
Robin K. Dore, MD, Inc.
Clinical Research
12791 Newport Ave., Suite 201
Tustin, CA 92780
T.714.505.5500
F.714.505.3381
Email: research@robinkdoremd.com
Dr Dore’s studies are summarized below.
Ongoing and Past Clinical Research Study Collaborative Protocols Summary
2000-Current:
AbbVie (Abbott):
- ABT-494 (JAK), multi center, randomized, treatment for RA: 2015→ongoing
- adalimumab, multi center, randomized, treatment for RA, extension studies
- adalimumab, multi center, randomized, treatment for Axial Spondyloarthritis
Amgen:
- brodalumab, multi center, randomized, treatment for PsA
- romosozumab, multi center, randomized, treatment for OP
- denosumab multi center, randomized, treatment for OP
- etanercept multi center, randomized, treatment for RA; open label extension study
- anakinra, multi center, randomized, treatment for RA
- etanercept, multi center, etanercept and MTX, mono/combo therapy, PsA; 2015→ongoing
AztraZenca:
- fostamatinib disodium, multi center, randomized, treatment for RA
Bristol-Myers Squibb:
- SQ abatacept, multi center, randomized, treatment for early RA
Biogen:
- 2-Part, multi center, Eval safety and efficacy of sq BIIB059, SLE/CLE, 2016→ongoing
Eli Lilly & Co.:
- ixekizumab, multi center, randomized, treatment for PsA: 2015→ongoing
- arzoxifene, multi center, randomized, treatment for OP
- teriparatide, multi center, randomized, tx for; OP, GIOP, device, observational
- raloxifene, multi center, randomized, treatment for OP
GlaxoSmithKline:
- GW406381 (cox-2) multi center, randomized, treatment for RA
- belimumab, Auto-injector Device, multi center, SLE subjects
HMR:
- risedronate, multi center, randomized, treatment for OP; compliance
Human Genome Science/GSK:
- belimumab, multi center, randomized, treatment for SLE
Knoll:
- RA observational trial for RA meds
Merck:
- alendronate, multi center, randomized, treatment for OP
- rofecoxib, multi center, randomized, treatment for RA
- zostavax, multi center, randomized, treatment for shingles vaccination
Novartis:
- secukinumab, multi-center, safety/efficacy of secukinumab, PsA, 2016→ongoing
NPS Allelix:
- PTH 1-84, multi center, randomized, treatment for OP
Optime:
- liposome-encapsulated diclofenac analgesic (LEDA) multi center, randomized, treatment for OA knee
Oxford Outcomes:
- Osteoporosis Questionnaire validation studies
Pfizer:
- tofacitinib, 5mg multi center, randomized, treatment for RA; 2014→ongoing
- tofacitinib, 11 mg XR multi center, randomized, treatment for RA; 2017→ongoing
Regeneron:
- iL1, multi center, randomized, treatment for RA
Roche:
- ibandronate, multi center, randomized, treatment for OP
- tocilizumab, multi center, randomized, treatment for RA; open label extension study
Sanofi Aventis:
- sarilumab, multi center, randomized, treatment for Ankylosing Spondylitis
- sarilumab, multi center, randomized, treatment for RA
Serono:
- onercept, multi center, randomized, treatment for Psoriasis and Plaque Psoriasis
UCB:
- certolizumab pegol, multi center, randomized, treatment for RA
Vertex: V
- X-509 (JAK3) multi center, randomized, treatment for RA
